Metastatic melanoma: Does adding a PD-1 inhibitor to targeted therapy help?

Results of the phase 3 COMBI-i trial for progression-free survival announced
Medicom Staff writer
DNA - suggesting BRAF mutation

AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.

Patients with unresectable or metastatic melanoma given a programmed cell death protein 1 (PD-1) inhibitor in addition to therapies targeting BRAF and MEK inhibition did not have significantly better progression-free survival, trial results show.